Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add ‐on mirabegron therapy to solifenacin (BESIDE)

ConclusionThe comparable frequency of CV‐related TEAEs, changes in vital signs and ECG parameters indicates no synergistic effect on CV safety outcomes when mirabegron and solifenacin are combined.

Source: International Journal of Clinical Practice - March 1, 2017 Category: Internal Medicine Authors: Marcus J. Drake, Scott MacDiarmid, Christopher R. Chapple, Adil Esen, Stavros Athanasiou, Javier Cambronero Santos, David Mitcheson, Sender Herschorn, Emad Siddiqui, Moses Huang, Matthias Stoelzel Tags: ORIGINAL PAPER Source Type: research